Current-state opacity verification in discrete event systems using an observer net.

Due to the proliferation of contemporary computer-integrated systems and communication networks, there is more concern than ever regarding privacy, given the potential for sensitive data exploitation. A recent cyber-security research trend is to focus on security principles and develop the foundations for designing safety-critical systems. In this work, we investigated the problem of verifying current-state opacity in discrete event systems using labeled Petri nets. A system is current-state opaque provided that the current-state estimate cannot be revealed as a subset of secret states. We introduced a new sub-model of the system, named an observer net. The observer net have the same structure as the plant, but it is distinguished by the use of colored markers as well as simultaneous and recursive transition enabling and firing, which offer an efficient state estimation. We considered two settings of the proposed approach: an on-line setting, in which a current-state opacity algorithm is proposed. The algorithm waits for the occurrence of an observable event and determines if the current observation of a plant reveals the secret behaviour, as well as, an off-line setting, where the verification problem is solved based on a state estimator called a colored estimator. In this context, necessary and sufficient conditions for verifying opacity are developed with illustrative examples to demonstrate the presented approach.

Design, synthesis of novel Triazolones and bis-Triazolones derivatives under ultrasound irradiation and evaluation as potent angiotensin converting enzyme (ACE) inhibitors.

The condensation of several primary amines and diamines with various N1-ethoxycarbonyles N1-tosylhydrazonates (1a-b), triazolones (2) and bis-triazolone (3) resulted in ethanol under ultrasound irradiation. Compared with the conventional methods, the main advantages of the present procedure are milder conditions, shorter reaction time and higher yields. The newly synthesized compounds were evaluated for angiotensin I-converting enzyme (ACE) inhibition. The results were compared to Captopril as a reference drug. Compounds 3b, 2h, 3a, 2d, and 2f showed not only inhibition activity with IC50 values of 0.162, 0.253, 0.253, 0.281 and 0.382 µM, respectively, but also minimal toxicity. The docking of chemical compounds in the ACE active site showed possible inhibitory effect of all compounds on the catalytic activity of the enzyme, which would satisfactorily explain the anti-hypertensive effect of these compounds.